Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-28Clinical Trial Update: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) [Phase 3]
Phase 3 trial evaluating pembrolizumab/vibostolimab with chemoradiotherapy followed by pembrolizumab/vibostolimab versus durvalumab in stage…
-
CLINICAL_TRIALS trial_result · 2026-08-27Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing JDQ443 with docetaxel in locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer is currently act…
-
CLINICAL_TRIALS trial_result · 2026-08-25Clinical Trial Update: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma [Phase 3]
Phase 3 clinical trial evaluating response- and biology-based risk factor-guided therapy in younger patients with non-high risk neuroblastom…
-
CLINICAL_TRIALS trial_result · 2026-08-21Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing JDQ443 with docetaxel in locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer is active not re…
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-08-19Clinical Trial Update: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
A Phase 3 clinical trial update evaluating how well and safely different treatments work in non-small cell lung cancer patients; completed.
-
EMA approval · 2026-08-18EMA Authorised: Tagrisso (osimertinib mesilate) — AstraZeneca AB
Authorised status for Tagrisso (osimertinib mesilate) by EMA for non-small cell lung cancer, marking regulatory approval in the European Uni…
-
CLINICAL_TRIALS trial_result · 2026-08-18Clinical Trial Update: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating JDQ443 vs docetaxel in locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2026-08-18Clinical Trial Update: A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial update for CS1001 in stage IV non-small cell lung cancer has completed.
-
FDA approval · 2026-08-14FDA Approved: ALECENSA — Supplemental Application (Genentech, Inc.)
Supplemental application for Alecensa (alectinib hydrobromide) submitted by Genentech, Inc. for regulatory action related to an approved ind…
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating HBI-8000 in combination with nivolumab for melanoma, renal cell carcinoma, and non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2026-07-28Clinical Trial Results: Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating durvalumab, tremelimumab, and selumetinib in recurrent or stage IV non-small cell lung cancer completed with post…
-
CLINICAL_TRIALS trial_result · 2026-07-28Clinical Trial Results: A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib [Phase 2]
Phase 2 trial evaluating continued dosing/follow-up for patients previously exposed to poziotinib; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Update: Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC [Phase 3]
Phase III study evaluating toripalimab plus chemotherapy versus placebo plus chemotherapy in resectable stage II-III non-small cell lung can…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
CLINICAL_TRIALS trial_result · 2026-07-22Clinical Trial Results: Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) [Phase 2]
Phase 2 trial evaluating atezolizumab in combination with induction chemotherapy and chemoradiotherapy for non-small cell lung cancer with s…
-
EMA approval · 2026-07-21EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
Roche's Tecentriq (atezolizumab) has been authorised by the EMA for multiple indications including transitional cell carcinoma, non-small ce…
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects [Phase 1, Phase 2]
Phase 1/2 trial assessing SBRT with immunotherapy for early-stage non-small cell lung cancer, focusing on tolerability and lung effects.
-
EMA approval · 2026-07-16EMA Authorised: Rybrevant (amivantamab) — Janssen-Cilag International N.V.
EMA authorises Rybrevant (amivantamab) for non-small cell lung carcinoma.
-
CLINICAL_TRIALS trial_result · 2026-07-13Clinical Trial Results: A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment [Phase 2]
Phase 2 trial evaluating sotorasib (AMG 510) for first-line treatment in stage IV non-small cell lung cancer with KRAS p.G12C mutation; stud…
-
CLINICAL_TRIALS trial_result · 2026-07-13Clinical Trial Results: A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
Phase 1/2 trial results for TC-510 in advanced mesothelin-expressing cancers were terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2026-07-07Clinical Trial Update: A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer [Phase 3]
A Phase 3 trial comparing SB27 to Keytruda in metastatic non-squamous non-small cell lung cancer is currently active but not recruiting.
-
EMA approval · 2026-07-03EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.
Authorization of Retsevmo (selpercatinib) by EMA for use in non-small cell lung cancer and thyroid neoplasms.
-
EMA approval · 2026-07-03EMA Authorised: Cejemly (sugemalimab) — Cstone Pharmaceuticals Ireland Limited
EMA has authorised Cejemly (sugemalimab) for non-small cell lung carcinoma, with Cstone Pharmaceuticals Ireland Limited as the marketing aut…
-
EMA approval · 2026-07-03EMA Authorised: Lorviqua (Lorlatinib) — Pfizer Europe MA EEIG
Lorviqua (lorlatinib) has been authorised for use in Europe for non-small cell lung carcinoma.